IgA Nephropathy (IgAN) - Pipeline Insight, 2024

IgA Nephropathy (IgAN) - Pipeline Insight, 2024

DelveInsight’s, “IgA Nephropathy – Pipeline Insight, 2024,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in IgA Nephropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

IgA Nephropathy Understanding

IgA Nephropathy: Overview

IgA nephropathy, also known as Berger’s disease, is a kidney disease that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. It is not known what causes IgA deposits in the glomeruli. In more than 10% of affected families, it is inherited. Each person may have a different set of signs and symptoms from IgAN. The Most common symptoms are: Hematuria and Proteinuria, Swelling in ankles and High Blood pressure. Urine test, Blood test, Glomerular Filtration rate, Kidney Biopsy are some of the procedures that helps in the diagnosis of IgA Nephropathy. There is no cure for IgA nephropathy, but treatments can help to prevent more damage to your kidneys.

""IgA Nephropathy - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the IgA Nephropathy pipeline landscape is provided which includes the disease overview and IgA Nephropathy treatment guidelines. The assessment part of the report embraces, in depth IgA Nephropathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, IgA Nephropathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence IgA Nephropathy R&D. The therapies under development are focused on novel approaches to treat/improve IgA Nephropathy.

IgA Nephropathy Emerging Drugs Chapters

This segment of the IgA Nephropathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

IgA Nephropathy Emerging Drugs

• Atrasentan: Chinook Therapeutics

Atrasentan is a potent and selective, small molecule inhibitor of the endothelin A receptor for the potential treatment of IgA Nephropathy (IgAN) and other proteinuric glomerular diseases. Chinook Therapeutics has initiated a phase III trial (ALIGN) of Atrasentan in early 2021 in patients with IgAN at high risk of kidney function decline.

• Sparsentan: Travere Therapeutics

Sparsentan is a novel small-molecule candidate in Phase III development for the treatment of IgA nephropathy (IgAN). IgAN, also called Berger’s disease, is a type of glomerulonephritis. Sparsentan is a single molecule designed to selectively block the receptors of two pathways which are associated with kidney disease progression. The receptors are endothelin 1A and angiotensin II type 1. In March 2022, Travere Therapeutics, Inc. announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).

Further product details are provided in the report……..

IgA Nephropathy: Therapeutic Assessment

This segment of the report provides insights about the different IgA Nephropathy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in IgA Nephropathy

There are approx. 30+ key companies which are developing the therapies for IgA Nephropathy. The companies which have their IgA Nephropathy drug candidates in the most advanced stage, i.e. Preregistration include, Travere Therapeutics.

• Phases

DelveInsight’s report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

IgA Nephropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

IgA Nephropathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses IgA Nephropathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging IgA Nephropathy drugs.

IgA Nephropathy Report Insights

• IgA Nephropathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

IgA Nephropathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing IgA Nephropathy drugs?
• How many IgA Nephropathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of IgA Nephropathy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the IgA Nephropathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for IgA Nephropathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Aravive
• Aduro BioTech
• Alnylam Pharmaceuticals
• Chinook Therapeutics
• Transcenta Holding
• Novartis Pharmaceuticals
• Ionis Pharmaceuticals
• Merck Serono
• ZymoGenetics

Key Products

• Cemdisiran
• BION 1301
• Batiraxcept
• TST 004
• LNP023
• IONIS-FB-LRx
• Atacicept